86PCabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models

Background: Cabozantinib (C) is a tyrosine kinase inhibitor against VEGFR2, RET, MET and AXL that has demonstrated clinical activity in RCC and 2L HCC and has been shown to promote an immune-permissive environment. C is undergoing clinical trials in combination with immune checkpoint inhibitors (ICI). The objectives of this preclinical study were to determine systemic cytokine profile changes induced by the combination with αPD1 and to assess cooperativity in anti-tumoral effects.

from A via a.sfakia on Inoreader https://ift.tt/2Gj7LiP